Rafael Holdings Clinical Trial Data
Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C. While the study did not achieve statistical significance on the primary endpoint in the overall population, a prespecified analysis of patients on background therapy (83% of the study) showed a statistically significant slowing of disease progression. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026.
- Counterparty
- Cyclo Therapeutics, LLC
- Term
- 96 weeks
- Earnings call
- Sep 30, 2026, 8:30 AM ET